MLYS Mineralys Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MLYS

Price (delayed)

$26.89

Market cap

$2.38B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.19

Enterprise value

$2.34B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 3
Highlights
The company's quick ratio has surged by 134% YoY but it fell by 22% QoQ
MLYS's equity has surged by 76% year-on-year but it is down by 14% since the previous quarter
The net income has dropped by 130% since the previous quarter and by 83% year-on-year
The EPS has dropped by 110% since the previous quarter and by 18% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: https://mineralystx.com
Peers: AMGN GILD VRTX REGN

Key stats

What are the main financial stats of MLYS

MLYS stock price

How has the Mineralys Therapeutics stock price performed over time
Intraday
-8.54%
1 week
-2.36%
1 month
4.83%
1 year
-28.58%
YTD
-25.9%
QTD
-0.33%

Financial performance

How have Mineralys Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$370.79M
Net income
-$349.58M
Gross margin
N/A
Net margin
N/A
The net income has dropped by 130% since the previous quarter and by 83% year-on-year
The company's operating income has shrunk by 116% QoQ and by 83% YoY

Price vs fundamentals

How does MLYS's price correlate with its fundamentals

Growth

What is Mineralys Therapeutics's growth rate over time

Valuation

What is Mineralys Therapeutics stock price valuation
P/E
N/A
P/B
4.03
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has dropped by 110% since the previous quarter and by 18% year-on-year
MLYS's equity has surged by 76% year-on-year but it is down by 14% since the previous quarter
The stock's P/B is 7% more than its last 4 quarters average of 4.1

Efficiency

How efficient is Mineralys Therapeutics business performance
MLYS's ROE has shrunk by 108% QoQ but it is up by 18% YoY
The ROA has dropped by 100% since the previous quarter but it is up by 17% year-on-year
MLYS's ROIC has plunged by 84% from the previous quarter but it is up by 44% YoY

Dividends

What is MLYS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MLYS.

Financial health

How did Mineralys Therapeutics financials performed over time
The company's quick ratio has surged by 134% YoY but it fell by 22% QoQ
The current ratio has soared by 128% YoY but it has decreased by 22% from the previous quarter
Mineralys Therapeutics's debt is 82% lower than its equity
MLYS's equity has surged by 76% year-on-year but it is down by 14% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.